Literature DB >> 24696312

Doxazosin in the treatment of scorpion envenomation.

Capan Konca1, Mehmet Tekin, Mehmet Turgut.   

Abstract

OBJECTIVE: To investigate effectiveness and applicability of Doxazosin in the treatment of scorpion stings in patients who had systemic symptoms.
METHODS: The medical records of patients were retrospectively reviewed, and the following data were collected: age, sex, clinical symptoms (localized and systemic), vital signs, information on the date and place of the sting occurrence, the anatomical sting site, time between sting and arrival to the hospital, scorpion identification, severity of the symptoms and treatment.
RESULTS: Of the victims, 48.5 % (n = 16) were males, and 51.5 % (n = 17) were females, with a mean age of 6.8 ± 4.2 y. The most common sting site was lower extremity 72.7 % (n = 24). Systemic toxicity (class II) was seen in 93.9 %, and two patients (6.1 %) manifested evidence of severe envenomation (class III). Both local and systemic effects were seen in the patients. Cold extremities persisted for 4.5 ± 1.5 h after administration of Doxazosin. Mean hospitalization time was 2.5 ± 1.5 d (range: 1.5 to 6 d). Thirty-two patients recovered without any sequel, whereas one patient died due to cardio-pulmonary insufficiency.
CONCLUSIONS: Doxazosin, especially if Prazosin is not available, can be recommended as an effective drug in the treatment of serious scorpion envenomations with significant sympathetic symptoms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24696312     DOI: 10.1007/s12098-014-1423-6

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  22 in total

1.  Cardiac arrest following scorpion envenomation.

Authors:  Ken Dittrich; Raees Ahmed; Qanta A A Ahmed
Journal:  Ann Saudi Med       Date:  2002 Jan-Mar       Impact factor: 1.526

2.  Prazosin: a pharmacological antidote for scorpion envenomation.

Authors:  V Gupta
Journal:  J Trop Pediatr       Date:  2006-03-14       Impact factor: 1.165

3.  Classification of clinical consequences of scorpion stings: consensus development.

Authors:  Asmae Khattabi; Rachida Soulaymani-Bencheikh; Sanae Achour; Louis-Rachid Salmi
Journal:  Trans R Soc Trop Med Hyg       Date:  2011-05-23       Impact factor: 2.184

4.  Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

Authors:  R R Miller; N A Awan; K S Maxwell; D T Mason
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

5.  Scorpion envenomation in children: an analysis of 99 cases.

Authors:  Mehmet Uluğ; Yöntem Yaman; Ferda Yapici; Nuray Can-Uluğ
Journal:  Turk J Pediatr       Date:  2012 Mar-Apr       Impact factor: 0.552

Review 6.  Autonomic effects of some scorpion venoms and toxins.

Authors:  Matthew C E Gwee; Selvanayagam Nirthanan; Hoon-Eng Khoo; Ponnampalam Gopalakrishnakone; R Manjunatha Kini; Li-Sam Cheah
Journal:  Clin Exp Pharmacol Physiol       Date:  2002-09       Impact factor: 2.557

7.  Clinical profile of severe scorpion envenomation in children at rural setting.

Authors:  Himmatrao S Bawaskar; Promodini H Bawaskar
Journal:  Indian Pediatr       Date:  2003-11       Impact factor: 1.411

8.  Management of scorpion sting: prazosin or dobutamine.

Authors:  B D Gupta; M Parakh; A Purohit
Journal:  J Trop Pediatr       Date:  2009-08-26       Impact factor: 1.165

9.  Utility of scorpion antivenin vs prazosin in the management of severe Mesobuthus tamulus (Indian red scorpion) envenoming at rural setting.

Authors:  H S Bawaskar; P H Bawaskar
Journal:  J Assoc Physicians India       Date:  2007-01

Review 10.  Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia.

Authors:  B Fulton; A J Wagstaff; E M Sorkin
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

View more
  1 in total

1.  Systemic manifestations in children with scorpion sting envenomation: how to manage?

Authors:  Subramanian Mahadevan; Ramachandran Rameshkumar
Journal:  Indian J Pediatr       Date:  2015-02-18       Impact factor: 1.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.